MC
EIKN

Merck & Co’s Eikon Therapeutics EIKN Stock Holding History

Merck & Co’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7M Hold
1,666,666
– – 4.13% 5
2026
Q1 		$17.6M Buy
+1,666,666
New +$22.3M 5.05% 5

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Merck & Co's EIKN Position: Q2 2026 in Review

Merck & Co held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 1,666,666 shares worth $21.7M. The position accounts for 4.13% of the portfolio, ranked #5.

Merck & Co first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Merck & Co held 1,666,666 shares of Eikon Therapeutics worth $21.7M as of Q2 2026.
  • Merck & Co left its Eikon Therapeutics share count unchanged in Q2 2026.
  • Eikon Therapeutics made up 4.13% of Merck & Co's portfolio in Q2 2026, its #5 holding.
  • Merck & Co first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.